

## J&J completes acquisition of Auris Health

03 April 2019 | News

**Auris will enable Johnson & Johnson to deliver on the promise of digital surgery and drive better outcomes for patients**



Johnson & Johnson announced that its subsidiary Ethicon has completed the acquisition of Auris Health for approximately \$3.4 billion in cash. Additional contingent payments of up to \$2.35 billion, in the aggregate, may be payable upon reaching certain predetermined milestones. With Auris Health's robotic platform technology, currently used in diagnostic and therapeutic procedures in the lung, Johnson & Johnson will advance its commitment to combatting lung cancer and expand its digital surgery portfolio across multiple surgical specialties.

The Auris technology complements robotic platform technologies currently in development in general surgery with Verb Surgical, through the Johnson & Johnson collaboration with Verily, and in orthopaedics with the acquisition of Orthotaxy. Johnson & Johnson aspires to bring disruptive innovation to the full continuum of procedures, including open, laparoscopic, robotic and endoluminal.

The company will discuss the transaction further during its next quarterly earnings call on April 16, 2019.